Clinical Trial Update: A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China [Phase 2]

View source ↗

Summary

Phase 2 study evaluating lorlatinib in ALK inhibitor-treated ALK-positive non-small cell lung cancer in China has completed, and results were posted in October …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2021-10-26